Elastin-derived peptides as immune-mediated drivers of vascular smooth muscle osteogenic transdifferentiation

Hypothesis

Elastin fragmentation releases elastin-derived peptides (EDPs) that act as endogenous danger‑associated molecular patterns (DAMPs). These EDPs bind Toll‑like receptor 2 (TLR2) on vascular smooth muscle cells (VSMCs), triggering MyD88‑dependent NF‑κB activation. NF‑κB cooperates with TNFα‑induced Msx2‑Wnt signaling to amplify β‑catenin nuclear translocation, which directly up‑regulates Runx2 and drives osteogenic transdifferentiation. In this model, the immune system does not merely respond to arterial aging; neutrophil‑derived elastase and monocyte‑derived TNFα cooperate to generate EDPs that lock VSMCs into a bone‑like state.

Testable Predictions

1. Pharmacologic blockade of elastase in aged mice will reduce arterial EDP levels, lower VSMC TLR2 signaling, and decrease Runx2 expression without changing total elastin content.
2. Genetic deletion of TLR2 specifically in VSMCs will blunt TNFα‑induced osteogenic programs, preserving contractile markers (SM22α, SMα‑actin) despite ongoing inflammation.
3. Administration of synthetic EDPs to young mice will recapitulate arterial stiffness and VSMC osteogenic changes, an effect abolished by TLR2 antagonism or MyD88 deficiency.
4. Combined inhibition of elastase and TLR2 will produce additive reductions in pulse wave velocity compared with either intervention alone, indicating synergistic immune‑mediated calcification.

Experimental Approach

• Use aged (24‑month) wild‑type and elastase‑deficient (neutrophil‑specific elastase knockout) mice; treat subsets with a selective TLR2 antagonist (e.g., CU‑CPT22).
• Measure aortic pulse wave velocity, elastin content (Verhoeff‑Van Gieson staining), and EDP levels by ELISA.
• Isolate aortic VSMCs for qPCR and immunoblot of Runx2, SM22α, phosphorylated β‑catenin, and NF‑κB p65.
• Perform bone‑specific staining (Alizarin Red) to quantify calcification.
• Include controls: young mice, vehicle‑treated aged mice, and VSMC‑specific Tlr2 knockout via Cre‑loxP.

Potential Outcomes and Falsification

If elastase inhibition or TLR2 loss fails to reduce VSMC Runx2 upregulation or arterial stiffness despite lowered EDP levels, the hypothesis that EDPs act through TLR2 to drive osteogenic transdifferentiation would be falsified. Conversely, a significant improvement in functional stiffness without elastin restoration would support the idea that immune‑generated elastin fragments are sufficient to program vascular aging.

Broader Implications

Targeting the elastase‑TLR2‑EDP axis could decouple inflammation from structural decline, offering a therapeutic route that mimics the benefits of exercise observed in aged rodents—reduced stiffness without elastin regeneration—by directly interrupting the immune‑mediated phenotypic switch of VSMCs.